Register Login
Register to leave comments
  • News bot Jan. 8, 2026, 1:02 p.m.

    📋 MOONLAKE IMMUNOTHERAPEUTICS (MLTX) - Clinical Trial Update

    Filing Date: 2026-01-08

    Accepted: 2026-01-08 08:00:54

    Event Type: Clinical Trial Update

    Event Details:

    MoonLake Immunotherapeutics (MLTX) Announces Clinical Trial Update MoonLake Immunotherapeutics (MLTX) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: opportunities
    • Diseases/Conditions: inflammat
    • Clinical Stage: clinical trial
    • Collaboration: U.S. FDA
      • anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, the risk that interim data analyses conducted prior to database lock and based on a limited number of patients having reached the relevant time point are not consistent with final data, risks and uncertainties associated with MoonLake’s business in general and limited operating history, difficulty enrolling patients in clinical trials, state and federal healthcare reform measures that could result in reduced demand for MoonLake’s product candidates and reliance on third parties to conduct and support its preclinical studies and clinical trials and the other risks described in or incorporated by reference into MoonLake’s Annual Report on Form 10-K for the year ended December 31, 2024

    🔬 Clinical Development Pipeline (MOONLAKE IMMUNOTHERAPEUTICS):

    Product Type Development Stage Therapeutic Area Source
    Placebo DRUG Phase PHASE3 Arthritis, Psoriatic ClinicalTrials.gov
    Risankizumab DRUG Phase PHASE3 Arthritis, Psoriatic ClinicalTrials.gov
    Adalimumab DRUG Phase PHASE2 Arthritis, Psoriatic ClinicalTrials.gov
    Sonelokimab DRUG Phase PHASE3 Arthritis, Psoriatic ClinicalTrials.gov
    NGS HLAA2 assay DEVICE Phase PHASE3 Patients With Non-Small Cell Lung Cancer ClinicalTrials.gov
    Docetaxel DRUG Phase PHASE3 Patients With Non-Small Cell Lung Cancer ClinicalTrials.gov
    OSE2101 DRUG Phase PHASE3 Patients With Non-Small Cell Lung Cancer ClinicalTrials.gov
    FR104 DRUG Phase PHASE1 Rheumatoid Arthritis ClinicalTrials.gov
    Sonelokimab (M1095) DRUG Phase PHASE2 Hidradenitis Suppurativa ClinicalTrials.gov
    BI 754091 DRUG Phase PHASE1 Solid Tumor, Adult ClinicalTrials.gov
    BI 765063 DRUG Phase PHASE1 Solid Tumor, Adult ClinicalTrials.gov
    Part C: OSE-279 600 mg - HLA-A2 negative DRUG Phase PHASE1 Solid Advanced Tumor ClinicalTrials.gov
    Part C: OSE-279 600 mg - HLA-A2 positif DRUG Phase PHASE1 Solid Advanced Tumor ClinicalTrials.gov
    Part C: OSE-279 600 mg and OSE2101 - HLA-A2 positive DRUG Phase PHASE1 Solid Advanced Tumor ClinicalTrials.gov
    Part B: OSE-279 600 mg and OSE2101 DRUG Phase PHASE1 Solid Advanced Tumor ClinicalTrials.gov
    Part A: OSE-279 600mg DRUG Phase PHASE1 Solid Advanced Tumor ClinicalTrials.gov
    Part A: OSE-279 300mg DRUG Phase PHASE1 Solid Advanced Tumor ClinicalTrials.gov
    Part A: OSE-279 100mg DRUG Phase PHASE1 Solid Advanced Tumor ClinicalTrials.gov
    OSE-127 DRUG Phase PHASE2 Ulcerative Colitis ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: MoonLake Immunotherapeutics
    • CIK: 0001821586
    • Ticker Symbol: MLTX
    • Period End Date: 2026-01-08
    • Document Type: 8-K

Search

News categories